A pilot study of hydroxyurea in hormone "escaped" metastatic carcinoma of the prostate.

Twenty-two patients with metastatic carcinoma of the prostate no longer responsive to hormonal therapy with stilboestrol 1 mg tds have been studied in a Phase II clinical trial of hydroxyurea 80 mg/kg body weight every third day after discontinuing their hormonal therapy. There was a partial objective response in 22.7%, a stable state response in 13.6% and… (More)